Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Mallinckrodt
AstraZeneca
McKinsey
Express Scripts

Last Updated: December 7, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR QSYMIA

See Plans and Pricing

« Back to Dashboard

All Clinical Trials for QSYMIA

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00796367 A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787) Completed Medpace, Inc. Phase 3 2008-12-01 The purpose of this study is to evaluate the long-term safety and efficacy of VI-0521 compared to placebo for the treatment of overweight and obesity in adults who have completed study OB-303 (NCT00553787) at selected study sites. This is an extension study of protocol OB-303 (NCT00553787).
NCT00796367 A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787) Completed VIVUS, Inc. Phase 3 2008-12-01 The purpose of this study is to evaluate the long-term safety and efficacy of VI-0521 compared to placebo for the treatment of overweight and obesity in adults who have completed study OB-303 (NCT00553787) at selected study sites. This is an extension study of protocol OB-303 (NCT00553787).
NCT01834404 Peripheral Pharmacodynamics of Phentermine-Topiramate in Obese Patients Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 4 2013-04-01 Our overall goal is to determine the effect of Phentermine and Topiramate ER on gastric emptying, gastric accommodation, satiety, and satiation in obese participants.
NCT01834404 Peripheral Pharmacodynamics of Phentermine-Topiramate in Obese Patients Completed Mayo Clinic Phase 4 2013-04-01 Our overall goal is to determine the effect of Phentermine and Topiramate ER on gastric emptying, gastric accommodation, satiety, and satiation in obese participants.
NCT02229214 Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects Completed VIVUS, Inc. Phase 4 2014-08-01 The main purpose of this study is measure the effect of VI-0521 on kidney function. Specifically, glomerular filtration rate (GFR) will be measured at baseline, after 4 weeks of study treatment, and after an additional 4 weeks of off-treatment recovery.
NCT02301416 Qsymia as an Adjunct to Surgical Therapy in the Superobese Active, not recruiting VIVUS, Inc. N/A 2014-12-01 This study tests the efficacy of the medication, Qsymia, as an adjunct therapy in superobese individuals planning to undergo weight loss surgery. Individuals taking the medication before and after surgery will be compared to historical controls who had surgery without taking the medication.
NCT02301416 Qsymia as an Adjunct to Surgical Therapy in the Superobese Active, not recruiting Wake Forest University Health Sciences N/A 2014-12-01 This study tests the efficacy of the medication, Qsymia, as an adjunct therapy in superobese individuals planning to undergo weight loss surgery. Individuals taking the medication before and after surgery will be compared to historical controls who had surgery without taking the medication.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for QSYMIA

Condition Name

Condition Name for QSYMIA
Intervention Trials
Obesity 6
Binge Eating Disorder 2
Adolescent Obesity 1
Metabolic Surgery 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for QSYMIA
Intervention Trials
Overweight 3
Bulimia 2
Binge-Eating Disorder 2
Disease 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for QSYMIA

Trials by Country

Trials by Country for QSYMIA
Location Trials
United States 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for QSYMIA
Location Trials
Ohio 2
Louisiana 1
California 1
North Carolina 1
Colorado 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for QSYMIA

Clinical Trial Phase

Clinical Trial Phase for QSYMIA
Clinical Trial Phase Trials
Phase 4 3
Phase 3 2
Phase 2 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for QSYMIA
Clinical Trial Phase Trials
Completed 4
Recruiting 3
Active, not recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for QSYMIA

Sponsor Name

Sponsor Name for QSYMIA
Sponsor Trials
VIVUS, Inc. 4
Lindner Center of HOPE 2
Wake Forest University Health Sciences 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for QSYMIA
Sponsor Trials
Other 7
Industry 6
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Dow
Express Scripts
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.